Please assess the completion status of the following clinical trial:

Trial Title: Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and nonpregnant, nonlactating female subjects ≥ 18 years of age.~2. Written informed consent Health Insurance Portability and Accountability Act authorization, and local patient privacy required documentation for this study have been obtained~3. Automated office blood pressure (AOBP) with SBP ≥ 130 mm Hg~4. Background antihypertensive treatment of ≥ 2 drugs~5. Serum cortisol ≥ 18 mcg/dL~Exclusion Criteria:~1. Concomitant use of epithelial sodium channel inhibitors or mineralocorticoid receptor antagonists~3. Subjects with hypokalemia~4. Subjects with hyperkalemia~5. Subjects with serum cortisol \< 3 mcg/dL~6. Subjects with serum sodium \< 135 mEq/L~7. Subjects with estimated glomerular filtration rate \< 60 mL/min/1.73m2~8. Subjects with type 1 or uncontrolled (hemoglobin A1c ≥ 9%) type 2 diabetes mellitus~9. Subjects with body mass index \> 40 kg/m2~10. Subjects with unstable angina~11. Subjects with SBP ≥ 175 mm Hg or DBP ≥ 100 mm Hg for Part 1 and SBP ≥ 160 mm Hg or DBP ≥ 100 mm Hg for Part 2 at Pre-Screening, Screening/Start of Placebo Run-in, or Randomization~12. Subjects with a decrease in SBP ≥ 20 mm Hg or DBP ≥ 10 mm Hg from sitting to standing position at screening~13. Subjects who, in the opinion of the investigator, have suspected nonadherence to antihypertensive treatment~14. Subjects who, in the opinion of the investigator, have any major medical illness or symptoms~15. Subjects who, in the opinion of the investigator, have any acute or chronic medical or psychiatric condition~16. Subjects undergoing treatment with any of the following medications:~1. Topical corticoids~2. Sympathomimetic decongestants~3. Theophylline~4. Phosphodiesterase type 5 inhibitors~5. NSAIDs~6. Intramuscular steroids~7. Estrogen~8. Cytochromes~9. Strong CYP3A and CYP3A4 inducers~   17. Subjects with known hypersensitivity to MLS-101 or any of the excipients~   18. Subjects who are night-shift workers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Part I) (Type: PLACEBO_COMPARATOR): Placebo tablet(s) by mouth once or twice daily.
- Dose 1 (Part I) (Type: EXPERIMENTAL): MLS-101 tablet(s) by mouth once or twice daily.
- Dose 2 (Part I) (Type: EXPERIMENTAL): MLS-101 tablet(s) by mouth once or twice daily.
- Dose 3 (Part I) (Type: EXPERIMENTAL): MLS-101 tablet(s) by mouth once or twice daily.
- Placebo (Part II) (Type: PLACEBO_COMPARATOR): Placebo tablet(s) by mouth once daily.
- Dose (Part II) (Type: EXPERIMENTAL): MLS-101 tablet(s) by mouth once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).